TY - JOUR
T1 - Synthetic polysulfated hyaluronic acid is a potent inhibitor for tumor necrosis factor production
AU - Chang, N. S.
AU - Intrieri, C.
AU - Mattison, J.
AU - Armand, G.
PY - 1994
Y1 - 1994
N2 - Based on the premise that naturally occurring glycosaminoglycans could serve as building blocks for synthesizing nontoxic drugs for suppression of tumor necrosis factor (TNF) production by inflammatory cells, we have chemically modified hyaluronic acid (HA) and tested its effects in blocking TNF-α and TNF-β production in vitro. HA was chosen mainly for its structural simplicity, nonimmunogenicity, and readiness for chemical modifications. When HA was chemically polysulfated to a sulfate/hexosamine molar ratio of 3.9, the sulfated HA, was shown to be a potent inhibitor of TNF-α production in lipopolysaccharide (LPS)- or interferon-γ-activated THP-1 cells. For example, a concentration of HA(s) as low as 10 ng/ml reduced TNF-α production in LPS-activated THP-1 cells more than 50%, whereas achieving a similar extent of reduction required 50 μg/ml native HA. By decreasing the extent of polysulfation, the inhibitory effect of HA(s) on TNF-α production was diminished. Other chemical modifications, including deacetylation, thiolation, or reduction of the carboxylic groups, could not increase the efficacy of HA in suppression of TNF-α production. Naturally polysulfated glycosaminoglycans, such as chondroitin sulfates, keratan sulfate, heparan sulfate, and heparin, failed to inhibit TNF-α production. HA(s) also restricted TNF-β (lymphotoxin) secretion in an Epstein-Barr virus-transformed B cell line, Roha-9, which constitutively produces TNF-β. HA(s) had no inhibitory effect on the proliferation of THP-1 or Roha-9 cells, which would account for the reduced TNF-α or TNF-β production. Furthermore, time-course metabolic labeling studies revealed that HA(s) could not restrict overall protein synthesis and secretion in THP-1 cells. However, HA(s) increased complement C1q secretion in THP-1 in a dose-dependent manner, but it had no effect on biosynthesis of complement C1 inhibitor, factor D, and Fcγ receptor type II (FcγRII). These results indicate that HA(s) selectively restricts the production of TNF-α, TNF-β, and probably several other protein species.
AB - Based on the premise that naturally occurring glycosaminoglycans could serve as building blocks for synthesizing nontoxic drugs for suppression of tumor necrosis factor (TNF) production by inflammatory cells, we have chemically modified hyaluronic acid (HA) and tested its effects in blocking TNF-α and TNF-β production in vitro. HA was chosen mainly for its structural simplicity, nonimmunogenicity, and readiness for chemical modifications. When HA was chemically polysulfated to a sulfate/hexosamine molar ratio of 3.9, the sulfated HA, was shown to be a potent inhibitor of TNF-α production in lipopolysaccharide (LPS)- or interferon-γ-activated THP-1 cells. For example, a concentration of HA(s) as low as 10 ng/ml reduced TNF-α production in LPS-activated THP-1 cells more than 50%, whereas achieving a similar extent of reduction required 50 μg/ml native HA. By decreasing the extent of polysulfation, the inhibitory effect of HA(s) on TNF-α production was diminished. Other chemical modifications, including deacetylation, thiolation, or reduction of the carboxylic groups, could not increase the efficacy of HA in suppression of TNF-α production. Naturally polysulfated glycosaminoglycans, such as chondroitin sulfates, keratan sulfate, heparan sulfate, and heparin, failed to inhibit TNF-α production. HA(s) also restricted TNF-β (lymphotoxin) secretion in an Epstein-Barr virus-transformed B cell line, Roha-9, which constitutively produces TNF-β. HA(s) had no inhibitory effect on the proliferation of THP-1 or Roha-9 cells, which would account for the reduced TNF-α or TNF-β production. Furthermore, time-course metabolic labeling studies revealed that HA(s) could not restrict overall protein synthesis and secretion in THP-1 cells. However, HA(s) increased complement C1q secretion in THP-1 in a dose-dependent manner, but it had no effect on biosynthesis of complement C1 inhibitor, factor D, and Fcγ receptor type II (FcγRII). These results indicate that HA(s) selectively restricts the production of TNF-α, TNF-β, and probably several other protein species.
UR - http://www.scopus.com/inward/record.url?scp=0028228672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028228672&partnerID=8YFLogxK
U2 - 10.1002/jlb.55.6.778
DO - 10.1002/jlb.55.6.778
M3 - Article
C2 - 8195703
AN - SCOPUS:0028228672
SN - 0741-5400
VL - 55
SP - 778
EP - 784
JO - Journal of Leukocyte Biology
JF - Journal of Leukocyte Biology
IS - 6
ER -